Rezdiffra (resmetirom) is a brand-name oral tablet prescribed for nonalcoholic steatohepatitis (NASH) in certain situations. It is typically taken once per day. The dosage varies based on a person’s ...
Rezdiffra (resmetirom) is a brand-name drug prescribed for a type of liver disease called metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH) ...
Please provide your email address to receive an email when new articles are posted on . Experts recommend confirming MASH diagnosis by assessing steatosis via ultrasound or FibroScan. MRI-proton ...
In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic ...
Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works. Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help ...
Credit: Madrigal Pharmaceuticals. Rezdiffra is supplied in 60mg-, 80mg-, and 100mg-strength tablets and is distributed through a limited specialty pharmacy network. Rezdiffra should be avoided in ...
Millions of Americans whose livers develop scar tissue due to a common disease now have the first approved drug, Rezdiffra, to treat the condition, the U.S. Food and Drug Administration announced ...
CONSHOHOCKEN, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...
Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results